Inhibition of Bromodomain and Extra Terminal (BET) Domain Activity Modulates the IL-23R/IL-17 Axis and Suppresses Acute Graft- Versus-Host Disease
- AUTHORS Snyder, et al
- Programs OPN-51107, Zavabresib (OPN-2853)
2021
Phase 1b/2a Study of PLX2853, a Small Molecule BET Inhibitor, in Subjects with Advanced Solid Tumors and Lymphoma
- AUTHORS Gordon, et al
- Programs Zavabresib (OPN-2853)
A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia
- AUTHORS Lee, et al
- Programs OPN-51107